Michael Carleton Email & Phone Number

Hoodsport, Wa, Us

United States

Managed IND-enabling studies and successful IND application to FDA for APR-1051 (WEE1 inhibitor)

Managed pre-clinical studies in support of INI-822, Inipharm's HSD17B13 inhibitor clinical lead under development for fibrotic liver diseases, including non-alcoholic steatohepatitis (NASH).

Supported pre-clinical development of MAVU-104, a first-in-class, orally active, small molecule inhibitor of ENPP1, an enzyme involved in the regulation of the STING pathway. Inhibiting ENPP1 activity with MAVU-104 allows for highly controlled enhancement of STING signaling in tumors without the need for injections. Mavupharma and the ENPP1 program was purchased by Abbvie in 2019.

Princeton Nj

Led pre-clinical and clinical efforts across matrix team to define and confirm mechanism(s) of action for selected IO assets and combinations for:-Innate immune cell agonists-Monocyte and myeloid cell agonists/depletors-Tumor and immune cell metabolismProvided subject matter expertise for due diligence activities and external project reviewsDeveloped and managed external collaborations in support of IO portfolio

Princeton Nj

Led efforts to integrate and analyze clinical datasets to facilitate: prospective patient segmentation into responder and non-responder populationsunderstanding(s) of IO mechanisms of resistance rational selection of IO therapeutic combinationsidentification of clinical correlates of response within the tumor microenvironmentProvided subject matter expertise for due diligence activities and external project reviewsManaged external collaborations in support of IO portfolio

Princeton Nj

-Directed IO biomarker strategy for Nivolumab in GBM Phase 2 and Phase 3 trials-Developed and translated IO biomarker plan for anti-CSF-1R Ph1a/b trial -Directed development of IO biomarker plan for anti-IL8 program-Worked within matrix environment to develop clinical strategy for anti-IL-8 and anti-CSF-1R-Worked within matrix environment to drive selection and clinical development of IO combinations-Managed external collaborations in support of IO portfolio-Provided subject matter expertise for due diligence activities and external project reviews

Seattle Wa

-Directed pre-clinical indication finding studies for internal drug development programs. -Directed research program focused on applying Presage proprietary intra-tumoral injection technology for the purpose of detecting localized immune responses within relevant tumor models in response to local injection of anti-cancer immune-modulatory agents.-Managed Presage/Celgene collaboration focused on application of Presage proprietary intra-tumoral injection platforms to combination drug efficacy screens in selected DLBCL and solid tumor xenografts.

Seattle Wa

-Led metabolic engineering efforts for enhanced production of lipid in cyanobacteria-Primary investigator for TGI as part of DOE funded National Alliance for Advanced Biofuels and Bio-products (NAABB)

Seattle Wa

-Primary investigator for TGI as part of DOE funded National Alliance for Advanced Biofuels and Bio-products (NAABB)-Led transcriptomics, metabolomics, next generation sequencing efforts in cyanobacteria -Led genetic screening and molecular tool development efforts in cyanobacteria -Established methods for wheat and corn genotyping

Seattle Wa

-Directed efforts to establish and apply transcriptomics to metabolic engineering of cyanobacteria-Directed efforts to apply context-specific genetic screens to gene discovery/pathway annotation of cyanobacteria-Directed efforts to establish GC and HPLC methods for metabolite analysis in cyanobacteria-Directed efforts to establish flow cytometry and microscopy methods for lipid body characterization and bacterial enumeration-Directed efforts to identify and validate cyanobacteria promoter elements for use in transgene expression studies

Seattle Wa

-Led efforts to translate/apply pharmacodynamic and response biomarkers to four phase I oncology clinical programs-Led efforts to apply lentiviral shRNA expression to investigate BRCA1 pathway function and synthetic lethality of PARP inhibition.-Led HTS efforts to identify/characterize mircoRNAs that disrupt cell cycle progression in tumor cells-Led efforts to identify microRNAs that function in myoblast, osteoblast, and T cell differentiation

Seattle Wa

-Led efforts to clone novel sphingosine phosphohydrolase (SPP2) and characterize its role in modulating S1P signaling-Led efforts to characterize the function of mitotic kinesin KIF14-Led HTS efforts to generate stable TP53 shRNA expressing cell lines -Led efforts to validate and characterize TP53 context specific genes identified in genome-wide chemosensitization RNAi-based screens-Led efforts to develop cell-based assays for screening small molecule ubiquitin ligase inhibitors in collaboration with Rigel Phamaceuticals-Collaborated on efforts to develop/optimize genome scale HTS methods for full genome siRNA screens as part of oncology target ID/validation efforts

Philadelphia Pa

-Identified and studied gene expression changes mediated by early growth response transcription factors and Notch during thymocyte development

Philadelphia Pa

Advisor: David L. Wiest-Determined early growth response transcription factors are necessary for thymocyte progression through the beta-selection checkpoint-Established a cell culture-based system to study the role of pre-TCR signaling in thymocyte development

Ph.D., Microbiology

Advisor: Dennis T. Brown -Studied structure and assembly of Sindbis virus envelope proteins

Ba, Microbiology

Activities and Societies: Microbiology Students Association